Oscar Health a new top pick at Baird

Baird analyst Michael Ha said Oscar Health (OSCR) is a new top pick as with the potential expiration of enhanced HIX subsidies looming, 2026 may pose some volatility from membership attrition + risk pool changes, but the firm believes the key to de-risking the thesis is diving deeper into the 2027 EPS bridge power. Baird also said they believe recent stock price weakness highlights a material dislocation of fundamentals versus. valuation, presenting a golden opportunity to buy the shares. Baird maintains its Outperform rating and $28 price target on Oscar Health shares.